help button home button Am J Pathol PCR Enhanced. PCRboost from Biomatrica
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gulley, M. L.
Right arrow Articles by Geradts, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gulley, M. L.
Right arrow Articles by Geradts, J.

American Journal of Pathology, Vol 152, 865-869, Copyright © 1998 by American Society for Investigative Pathology

REGULAR ARTICLES

Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product

ML Gulley, JM Nicholls, BG Schneider, MB Amin, JY Ro and J Geradts
Department of Pathology, University of Texas Health Science Center at San Antonio and The Audie L. Murphy Memorial Veteran's Hospital, 78284- 7750, USA. gulleym@uthscsa.edu

The p16/MTS1 gene is altered by deletion, mutation, or hypermethylation in a wide variety of human cancers. As a result of deficient p16 protein, these cancers lack a critical mechanism for halting G1/S cell cycle progression. In the current study, 59 cases of nasopharyngeal carcinoma were evaluated for expression of the p16 tumor suppressor protein by immunohistochemical analysis of paraffin-embedded tissue. There was no detectable p16 in 38/59 cases (64%), which implies a very high rate of p16 inactivation in this type of cancer. On the other hand, the retinoblastoma gene product, which also regulates the G1 to S phase transition of the cell cycle, was consistently expressed in nasopharyngeal carcinomas by immunohistochemical analysis. These results implicate p16 inactivation but not Rb alteration in the stepwise progression of nasopharyngeal carcinogenesis.


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Cerimele, T. Battle, R. Lynch, D. A. Frank, E. Murad, C. Cohen, N. Macaron, J. Sixbey, K. Smith, R. S. Watnick, et al.
Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma
PNAS, January 4, 2005; 102(1): 175 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. W. C. Lee, J.-H. Li, W. Shi, A. Li, E. Ng, T.-J. Liu, H. J. Klamut, and F.-F. Liu
p16 Gene therapy: A potentially efficacious modality for nasopharyngeal carcinoma
Mol. Cancer Ther., October 1, 2003; 2(10): 961 - 969.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
N. Ohtani, P. Brennan, S. Gaubatz, E. Sanij, P. Hertzog, E. Wolvetang, J. Ghysdael, M. Rowe, and E. Hara
Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5
J. Cell Biol., July 21, 2003; 162(2): 173 - 183.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Makitie, C. MacMillan, J. Ho, W. Shi, A. Lee, B. O'Sullivan, D. Payne, M. Pintilie, B. Cummings, J. Waldron, et al.
Loss of p16 Expression Has Prognostic Significance in Human Nasopharyngeal Carcinoma
Clin. Cancer Res., June 1, 2003; 9(6): 2177 - 2184.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C.-F. Hwang, C.-L. Cho, C.-C. Huang, J.-S. Wang, Y.-L. Shih, C.-Y. Su, and H.-W. Chang
Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy
Ann. Onc., August 1, 2002; 13(8): 1246 - 1251.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Society for Investigative Pathology.